Safety and efficacy of relacorilant and nab-paclitaxel in platinum resistant ovarian cancer: A GRADE assessed systematic review and meta-analysis of randomized controlled trials
Abstract
e17604
Background:
Relacorilant, a first-in-class selective glucocorticoid receptor antagonist, is being used along with Nab-Paclitaxel for the treatment of Platinum resistant ovarian cancer and has shown better results as compared to Nab-Paclitaxel alone. To systematically evaluate the efficacy and safety of Relacorilant in combination with nab-paclitaxel compared with nab-paclitaxel alone in patients with platinum-resistant ovarian cancer using a GRADE-appraisal meta-analysis of randomized controlled trials.
Methods:
Embase, PubMed, Cochrane, and ClinicalTrials.gov were searched through December 2025. Four Randomised Controlled Trials assessing the effects of Relacorilant and Nab-Paclitaxel in Platinum resistant ovarian cancer. Pooled analyses of Progression Free Survival (PFS), Overall Survival (OS), Duration of Response (DOR), and Objective Response Rate (ORR), with adverse effects including anemia, neutropenia, and urinary tract infections were performed using random-effects models in R 4.5.2 using “metafor” package. Heterogeneity was quantified using I² statistics.
Results:
A total of randomized controlled trials evaluating Relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in platinum-resistant ovarian cancer were included. The meta-analysis showed a numerical improvement in progression-free survival (PFS) with combination therapy (pooled mean difference [MD] 1.26 months, 95% CI 0.15 to 2.38) with low heterogeneity (I² = 0%). Overall survival (OS) also…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.